Junshi Biosciences Umumkan Hasil Analisis Akhir Studi Fase 3 NEOTORCH di Kongres ESMO 2026
Junshi Biosciences mengumumkan hasil uji klinis Fase 3 NEOTORCH yang positif untuk obat kanker toripalimab pada Kongres ESMO 2026. Terapi tersebut menunjukkan peningkatan signifikan dalam kelangsungan hidup bebas kejadian dan keseluruhan bagi pasien kanker paru-paru.
Junshi Biosciences presented positive final analysis results from its Phase 3 NEOTORCH study at the ESMO Congress 2026. The study evaluated perioperative treatment using toripalimab combined with chemotherapy in patients with resectable stage II-III non-small cell lung cancer. Results demonstrated statistically significant and durable improvements in both event-free survival and overall survival rates. The favorable clinical data reinforces toripalimab's therapeutic potential as an effective treatment option for lung cancer patients. Successful late-stage trials strengthen the company's position within the global oncology biopharmaceutical sector. Continued positive clinical outcomes may pave the way for expanded regulatory approvals and commercial adoption worldwide.
Penafian analisis AI
Analisis dampak aset dibuat oleh AI dan hanya untuk tujuan informasi. Ini bukan nasihat keuangan. Selalu lakukan riset sendiri sebelum mengambil keputusan investasi.
Diskusi